11 results
To test whether 100 mg doxycycline inhibits aneurysm growth
To assess the effect of low dose doxycycline on markers of neutrophilic inflammation and proteolytic activity stable GOLD III COPD patients.
To asses the short and long term effect on pain and function and the safety of doxycycline in patients with mild to severe pain due to established knee OA.
To compare the EPOS guideline with the free choice treatment of the GP for acute rhinosinusitis in general practice.
To assess the efficacy of two treatment strategies for fatigue and disabilities in QFS: long term treatment with doxycycline or cognitive behavioral therapy (CBT).
Primary objectives of INTACT III are:1) to prospectively compare the efficacy of Sacral Nerve Stimulation (SNS) with BOTOX® 100 U related to the Patient Perception of Bladder Condition (PPBC) questionnaire (Coyne 2006) and the reduction of urinary…
The purpose of this study is to evaluate the efficacy and safety of NIS793 in combination with gemcitabine/nab-paclitaxel versus gemcitabine/nab-paclitaxel and placebo in first-line mPDAC.This study aims to explore whether blockade of Transforming…
Safety Run-in (SRI) part:To confirm the recommended phase 2 dose (RP2D) of NIS793 or any other investigational drug(s), in combination with SOC anti-cancer therapy. In protocol amendment 1, an arm with tislelizumab has been added. In this arm, the…
To determine the efficacy of antibiotic prophylaxis after a tick bite in the Dutch setting, in relation to tick infection, tick engorgement and attachment time.
In this study we want to assess the hepatic cyst penetration capacity of intravenously administered antibiotics (ciprofloxacin, co-trimoxazole, doxycycline and piperacillin/tazobactam) by comparing blood and cyst fluid concentrations in patients…
Investigate whether treatment with azithromycin has an inhibitory effect on the mTOR pathway and/or C. acnes, causing a reduction of the inflammatory activity which is found in sarcoidosis patients measured by blood biomarkers ACE and sIL-2R and by…